HAYA Therapeutics: Funding, Investors & Team (Sep 2026)
HAYA Therapeutics is a company that develops RNA-based treatments for heart failure. Their therapies target a specific regulator of fibrosis in the heart, known as long noncoding RNA, in order to block myocardial fibrosis and effectively treat heart failure.
HAYA Therapeutics has raised $90.1M across 4 funding rounds on record, the most recent a Series A of $65.0M announced in May 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
HAYA Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2025.
HAYA Therapeutics Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
HAYA Therapeutics raised $20.1M in an undisclosed round announced in May 2021.
9 months later, a Seed of $5.0M was announced in Feb 2022.
2.6 years later, an undisclosed round was announced in Sep 2024 with no disclosed amount.
8 months later, a Series A of $65.0M was announced in May 2025.
HAYA Therapeutics Founders and Leadership Team
Contact details for the HAYA Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →HAYA Therapeutics Funding Compared to Other Biotechnology Startups
HAYA Therapeutics' latest round of $65.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like HAYA Therapeutics in Biotechnology and Lausanne
Companies Similar to HAYA Therapeutics
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
HAYA Therapeutics Funding FAQs
What does HAYA Therapeutics do?
HAYA Therapeutics is a company that develops RNA-based treatments for heart failure. Their therapies target a specific regulator of fibrosis in the heart, known as long noncoding RNA, in order to block myocardial fibrosis and effectively treat heart failure.
How much funding has HAYA Therapeutics raised?
HAYA Therapeutics has raised $90.1M across 4 rounds on record. The most recent is a Series A of $65.0M announced in May 2025.
When did HAYA Therapeutics last raise funding?
HAYA Therapeutics' most recent funding round on record is a Series A of $65.0M, announced in May 2025.
Who founded HAYA Therapeutics?
FundedIQ lists Daniel Blessing (Founder) at HAYA Therapeutics.
Who is the CEO of HAYA Therapeutics?
Samir Ounzain is listed as CEO at HAYA Therapeutics.
Where is HAYA Therapeutics headquartered?
HAYA Therapeutics is based in Lausanne, Vaud, Switzerland.
How many employees does HAYA Therapeutics have?
HAYA Therapeutics is in the 11-50 employee band.
How does HAYA Therapeutics' funding compare to other Biotechnology startups?
HAYA Therapeutics' latest round of $65.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's HAYA Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for HAYA Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.